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Real time-PCRAbstract Background: Circulating microRNAs (miRNAs) are endogenous, small (17–25 nucleo-
tides) non-coding RNAs that are overexpressed in many human cancers including hepatocellular
carcinoma (HCC). Moreover, circulating miRNAs can reﬂect the level of tissue miRNAs, so could
be potential tumor markers. miRNA-21 regulates post-transcriptional expression of tumor suppres-
sor gene; programed cell death 4 (PDCD4) gene which implies that miRNA-21 might be a novel
diagnostic and/or prognostic marker for cancer.
Objective: To evaluate the diagnostic and prognostic potential of circulating miRNA-21 and
study the expression of PDCD4 gene as a target of miRNA-21 in HCC in Egyptian patients.
Subjects and methods: This study was conducted on 30 HCC patients, 20 chronic liver disease
(CLD) patients due to HCV infection and 20 healthy subjects. Serum alpha fetoprotein (AFP)
was measured for all participants. The relative plasma expression of each of miRNA-21 and
PDCD4 gene was determined in whole blood samples using real-time polymerase chain reaction.
Results: The results revealed over expression of miRNA-21 and under expression of PDCD4
gene in HCC group (p< 0.05) compared to both CLD and healthy subjects, while no signiﬁcant
change was detected between CLD and healthy subjects. miRNA-21 expression was negatively cor-
related with PDCD4 gene expression. miRNA-21 expression increased signiﬁcantly with presence of
cirrhosis, increased number of focal lesions, larger size of tumor, advanced tumor stage and pres-
ence of vascular invasion. Receiver Operator of Characteristics (ROC) curve analysis of plasma
miRNA-21 revealed that, at a cut-off value of 3.93 (fold expression), the sensitivity and speciﬁcity
for differentiation of HCC cases were 93% and 90%, respectively.
Conclusion: Circulating miRNA-21 could be a novel early diagnostic and prognostic biomarker
for detection of HCC. Approaches interfering with the miRNA-21/PDCD4-axis, or releasing
PDCD4 expression, may have a strong basis for therapeutic uses in cancer in the future.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).a (HCC)
2 G. El Gedawy et al.1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer worldwide and is associated with liver cirrhosis (LC)
in 80% of cases [1]. In Egypt, the incidence rate of HCC has
increased sharply in the last decade [2]. The development
and progression of HCC is a complex process, which involves
the dysregulation of oncogenes and tumor suppressor genes. It
has previously been reported that microRNAs (miRNAs) are
essential in oncogenesis by the regulation of oncogenes and
tumor suppressor genes [3].miRNAs are approximately
22-nucleotide, noncoding, endogenous RNA molecules with
an important role in various cellular biological processes,
including embryonic development, cell differentiation, and
tumorigenesis [4]. miRNAs regulate post-transcriptional gene
expression, by binding to the 30-untranslated region
(30-UTR) of speciﬁc target messenger RNAs (mRNAs), which
in turn causes mRNA degradation or translational repression
[5,6]. In humans, more than 50% of miRNA genes are located
at fragile sites or in cancer-associated genomic regions that are
frequently involved in chromosomal abnormalities, such as
loss of heterozygosity, ampliﬁcation and breakpoints [7].
miRNA-21 is one of the ﬁrst oncogenic miRNAs with upreg-
ulation detected in many types of human cancer [8].
miRNA-21 has also been implicated in multiple malignancy-
related processes, including cell proliferation, apoptosis, inva-
sion and metastasis, by down regulating the expression of
speciﬁc target genes, such as phosphatase and tensin homolog
(PTEN), tropomyosin 1 (TPM1), programed cell death 4
(PDCD4) and B-cell lymphoma 2 (Bcl-2) [9].
PDCD4 is a tumor suppressor gene that plays an important
role in regulating apoptosis, invasion and metastasis [10]. Sev-
eral reports described the regulation of PDCD4 by miRNA-21.
In pancreatic ductal adenocarcinoma; inhibition of miRNA-21
reduces proliferation and increases cell death by increasing
PDCD4 [11]. Asangani et al. [12] found a conserved potential
site for miRNA-21 within the 30UTR (3-untranslated region)
of PDCD4 mRNA. Refs. [13,14] demonstrated the functional-
ity of this site as well as the regulation of PDCD4 levels by
miRNA-21 and induction of invasion, intravasation and
metastasis by elevated miRNA-21. Thus, miRNAs modulate
various cellular signaling pathways involved in cell growth,
proliferation, motility and survival [15].
Better understanding of the molecular mechanisms
involved in hepatocellular carcinogenesis contributes to the
identiﬁcation of novel prognostic and diagnostic biomarkers
and therapeutic targets for HCC. So, this study aimed to eval-
uate the diagnostic potential of circulating miRNA-21 and
study the expression of programed cell death 4 (PDCD4) gene
as a target of miRNA-21 in Egyptian patients with HCC and
correlating them to the clinical and path logical parameters of
the patients.
2. Subjects and methods
2.1. Study population
The work has been carried out in accordance with the code of
Ethics of the World Medical Association (Declaration of
Helsinki) for experiments in humans. The study was approved
by ethics committee of Faculty of Medicine and National LiverPlease cite this article in press as: El Gedawy G et al., Circulating MiRNA-21 and pro
in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.eInstitute, Menouﬁa University. Enrollment of individuals in
the study was conditioned by an obtained written informed
consent. Seventy subjects were enrolled in the study and were
divided into 3 groups. Fifty patients were randomly selected
from the inpatient ward and outpatient clinic, National Liver
Institute, Menouﬁa University from January 2014 to Decem-
ber 2014. Patients were subdivided to newly diagnosed naı¨ve
HCC patients and HCV positive chronic liver disease (CLD)
cases. The HCC group comprised 30 patients, 26 males and
4 females, their ages ranged from 30 to 52 years. The diagnosis
of HCC was based on clinical examination, laboratory tests,
ultrasonography and spiral CT. The CLD group consisted of
20 cases, 15 males and 5 females, and their ages ranged from
35 to 51 years. CLD patients were diagnosed by ultrasono-
graphical ﬁndings (shrunken liver, coarse echo pattern, atten-
uated hepatic vein and ﬁne nodular surface) and biochemical
evidence of parenchymal damage as well as liver biopsy.
Patients with bacterial or other viral infection, chronic renal
damage, Insulin-dependent diabetes mellitus (IDDM), other
malignant diseases, or undergoing interferon administration
or immune-suppressive or chemotherapy were excluded from
this study. In addition 20 apparently healthy subjects, 18 males
and 2 females, and their ages ranging from 32 to 53 years, age
and gender matching, served as the control group.
All patients and control groups were subjected to full his-
tory taking, complete clinical examination, abdominal ultra-
sonography and/or CT.
2.2. Laboratory investigations
Ten ml venous blood samples were collected from patients and
controls and divided into three parts. The ﬁrst part was col-
lected in plain tube and used for routine laboratory investiga-
tions, including liver function tests [using fully automated auto
111 analyzer SYNCHRON CX9ALX (Beckman Coulter Inc.,
CA, USA)] and immunoassay; serum HBs-Ag and HCV-Ab
[using (Abbott Laboratories, Abbott Park, IL, USA)]. Also,
serum AFP concentration was measured using the Automated
Chemiluminescence System (ACS: 180 provided by Siemens
Medical Solutions Diagnostics Corporation, USA). The sec-
ond part was collected in an ethylene diamine tetra acetic acid
(EDTA) containing tube and used for CBC assessment using
Sysmex K-21, (Sysmex Corporation, Kobe, Japan). The third
part was collected in an EDTA containing tube and used
immediately for RNA – miRNA extraction and molecular
testing.
2.3. Molecular testing
Real time PCR technology (using 7500 fast real time PCR –
TaqMan microRNA and RNA Control Assay) was used
for assessments of miRNA-21 and its control gene
(RNU43) and the tumor suppressor gene PDCD4 and its
control gene [Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH)].
2.4. Extraction and cDNA synthesis
2.4.1. RNA extraction and cDNA synthesis
RNA was extracted from fresh EDTA treated blood sample
using PureLink RNA Mini Kit (Ambion, Life Technology)gramed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC)
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Figure 2 Mean RQ of PDCD4 gene expression differences
between HCC, CLD and control groups.
Figure 3 Ampliﬁcation Plot (Rn vs. Cycle) of miRNA-21.
Circulating MiRNA-21 and PDCD 4 gene expression in HCC 3and QIAzol (Lysis solution) according to the manufacturer’s
instructions. RNA quantity was tested by spectrophotometer
at optical density; OD260 (RNA concentration = Diluted vol-
ume (lg/mL)  OD260  dilution factor). Then single stranded
cDNAs were synthesized using High Capacity cDNA Reverse
Transcription Kit according to the manufacturer’s instructions
(Applied Biosystems, CA, USA). Random Hexamer Primer
(2 lL), Reaction Buffer (2 lL), RNase Inhibitor (1 lL), dNTP
Mix (0.8 lL), MultiScribeTM Reverse Transcriptase (1 lL), and
nuclease-free water (3.2 lL) were mixed. Then cDNA synthesis
was done where RNA samples (10 lL) were added, mixed and
brieﬂy centrifuged with the previous prepared components.
The programing of thermal cycler condition was as follows:
heating at 25 C for 10 min, 37 C for 120 min, then, termina-
tion of the reaction by heating at 85 C for 5 min.
2.4.2. miRNA extraction and cDNA synthesis
miRNAs were extracted from fresh EDTA treated blood sam-
ple using Qiagen miRNA Extraction kit and QIAzol (Lysis
solution) according to the manufacturer’s instructions.
Single-stranded cDNAs were generated using TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA) via mixing RT Primer (3 lL), 10X RT Buffer
(1.5 lL), RNase Inhibitor (0.19 lL), dNTP mix (0.15 lL),
MultiScribeTM Reverse Transcriptase (1 lL), and nuclease-free
water (4.16 lL). RNA samples (5 lL) were added, mixed and
brieﬂy centrifuged with the previous prepared components.
The programing of thermal cycler condition was as the follow-
ing: hold for 30 min at 16 C, hold for 30 min at 42 C, then,
termination of the reaction by heating at 85 C for 5 min.
2.5. Amplification
Determination of miRNA-21 levels was done by TaqMan
miRNA Assay and PDCD4 expressed levels by TaqMan gene
expression assay using Universal TaqMan master mix
(Applied Biosystems, Thermo Fisher Scientiﬁc) according to
the manufacturer’s protocol. Fluorescence measurements were
made in every cycle (Figs. 3 and 4) and the cycling conditions
used for ampliﬁcation of genes of interest were: initial denatu-
ration step at 95 C for 10 min followed by 40 cycles of 95 C
for 15 s and 40 cycles of 60 C for 60 s. The primers for
miRNA-21, RNU43 (reference control gene), PDCD4 and
GAPDH (reference control gene) were supplied by Qiagen
Germany. miRNA-21 Forward Primer: 5-AGAAATGCCTG
GGTTTTTTTGGTT-3 and miRNA-21 Reverse Primer: 5-T0 
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Figure 1 Mean RQ of circulating miRNA-21 in HCC, CLD and
control groups.
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in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.eTGGGAATGCTTTTCAAAGAAGGT-3.RNU43 probe seq-
uence: GAACTTATTGACGGGCGGACAGAAACTGTGT
GCTGATTGTCACGTTCTGATT. PDCD4 Forward Pri-
mer: 5-CTTGAAGGTTAAGATGTGGGAGTGT-3 and PD
CD4 Reverse Primer: 5-AGCTAAACTCCAGAACTTTT
CCATT-3. GAPDH Forward Primer: 5-TGCCCAGTTGAA
CCAGGCG-3 and GAPDH Reverse Primer: 5-CGCGGAG
GGAGAGAACAGTGA-3.
2.6. Quantification
Quantiﬁcation of gene expression of interest was accomplished
by measuring the fractional cycle number at which the amount
of expression reached a ﬁxed threshold (Ct), which was directly
related to the amount of product. The relative quantiﬁcation
given by the Ct values was determined and the control gene Ct
subtracted to achieve DCt [DCt = Ct (gene of interest)  Ct
(control gene)]. Then relative expression level was determined
as 2(DDCt), where DD Ct = DCt (target sample)  DCt (refer-
ence sample).gramed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC)
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Figure 4 Ampliﬁcation Plot (Rn vs. Cycle) of PDCD4 gene.
Table 1 Pearson’s correlation between RQs of miRNA-21
and PDCD4 gene expressions in HCC Group.
Parameters HCC group
MicroRNA-21 RQ (folds)
r P-value
PDCD4 RQ (Folds) 0.428 <0.01
RQ: relative quantity. P< 0.01: highly signiﬁcant. PDCD4 gene:
programed cell death 4.
4 G. El Gedawy et al.2.7. Statistical analysis
Data were collected, tabulated and statistically analyzed by
IBM SPSS (Statistical Package for the social Science) ver-
sion 18.0 statistical package (SPSS, Inc, Chicago, IL, USA).
ANOVA, Student’s t test and Pearson’s correlation tests were
performed at 5% level of signiﬁcance. The diagnostic perfor-
mance for miRNA-21 and AFP to discriminate HCC cases
from those without HCC was evaluated using Receiver
Operating Characteristic (ROC) curve analysis. The sensitiv-
ity, speciﬁcity, positive predictive value (PPV), negative predic-
tive value (NPV) and overall accuracy for each marker were
determined.
3. Results
A total of 70 subjects were enrolled in this study, 30 HCC
patients (86% were males) with a mean age of 43.47
± 4.37 years, 20 CLD patients (75% were males) with a mean
age of 42.00 ± 6.88 years, and 20 healthy volunteers (90%
were males) with a mean age of 42.65 ± 5.72 years. The stud-
ied groups were homogenous in terms of age and gender
(p> 0.05).
Comparison between the studied groups regarding mean
relative quantities (RQs) of miRNA-21 and PDCD4 gene
expression revealed that there were signiﬁcant increase in
miRNA-21 and signiﬁcant decrease in PDCD4 gene expres-
sions in HCC group compared to each of CLD and control
groups (p< 0.05). However, they showed no signiﬁcant differ-
ence between CLD and control groups (p> 0.05) (Figs. 1 and
2).
Table 1 showed signiﬁcant inverse correlation (p< 0.01)
between miRNA-21 and PDCD4 gene expression RQs in
HCC group.Please cite this article in press as: El Gedawy G et al., Circulating MiRNA-21 and pro
in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.eRelationship between mean RQs of miRNA-21 and
PDCD4 gene expression and pathological characteristics of
HCC patients: The mean RQ of miRNA-21 showed signiﬁcant
increase with presence of cirrhosis, increased number of focal
lesions, larger size of tumor, advanced tumor stages (stages 3
& 4 vs stages 1 & 2) and presence of vascular invasion.
Meanwhile, the mean RQ of PDCD4 gene expression showed
a signiﬁcant decrease with increased number of focal lesions,
larger sized tumors and advanced stages of HCC (Tables 2
and 3). However, no signiﬁcant difference in serum AFP was
detected regarding the aforementioned variables (data not
shown).
The RQ of circulating miRNA-21 showed a highly signiﬁ-
cant elevation in HCC patients with early tumor development
(single focal lesion, tumor size <3 cm, and collectively TNM 1
and 2 stages) (p< 0.01) compared to each of the control and
CLD patients groups (Table 4), while no statistical difference
was detected regarding RQ of plasma PDCD4 gene expression
(data not shown).
Regarding correlation between the mean RQ of each of
miRNA-21 and PDCD4 gene expression and some biochemi-
cal parameters in the studied groups: There was a signiﬁcant
positive correlation (p< 0.01) between miRNA-21 and AFP
and signiﬁcant inverse correlation (p< 0.05) between PDCD4
and each of total and direct bilirubin in HCC group (Table 5).
A signiﬁcant positive correlation was detected between
miRNA-21 and ALT as well as between PDCD4 gene expres-
sion and GGT in CLD group (data not shown). Meanwhile,
No statistically signiﬁcant correlation was identiﬁed between
miRNA-21 and PDCD4 gene expression and any of these
studied parameters in control group (data not shown).
Receiver Operator of Characteristics (ROC) curve analysis
of AFP and miRNA-21: displayed that the best cut-off of
serum AFP for differentiation of HCC cases from those with-
out HCC was 91.7 ng/ml, at this cut-off; the sensitivity, speci-
ﬁcity, PPV, NPV and overall accuracy were 75.2%, 92.3%,
90.2%, 69.2%, and 77.0%, respectively. For miRNA-21 the
best cutoff was 3.93 RQ with sensitivity, speciﬁcity, PPV,
NPV and overall accuracy of 93%, 90%, 94.4%, 87.5%, and
92.5%, respectively. Combined use of both parameters was
superior to the use of AFP alone as the speciﬁcity, PPV, and
overall accuracy were 97%, 96%, and 92%, respectively
(Figs. 5 and 6 and Table 6).
4. Discussion
HCC as other malignancies is attributed to accumulated
genetic alterations. As an oncomir, miRNA-21 is upregulated
in a variety of human malignancies. Overexpression ofgramed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC)
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Table 2 Comparison between pathological criteria of HCC
regarding RQ of miRNA-21 in HCC group.
Studied
variables
MiRNA-21 expression
(fold change) in HCC group
(No = 30) (M± SD)
Student – t test P-value
Cirrhosis
Positive
(No = 26)
15.11 ± 12.7 4.39 <0.01
Negative
(No = 4)
3.8 ± 1.3
Number of focal lesions
Single
(No = 12)
6.15 ± 3.24 3.65 <0.01
Multiple
(No = 18)
18.6 ± 13.9
Size of tumor
<3 cm
(No = 9)
5.6 ± 2.5 4.08 <0.01
P3 cm
(No = 21)
18.2 ± 13.6
Vascular invasion
Positive
(No = 19)
17.4 ± 14 2.98 <0.01
Negative
(No = 11)
7.03 ± 4.4
Enlarged liver
Mild
(No = 27)
13.44 ± 12.8 0.206 >0.05
Moderate
(No = 3)
15.04 ± 11.4
Enlarged spleen
Mild
(No = 20)
14.71 ± 16.72 0.296 >0.05
Moderate
(No = 10)
13.0 ± 10.21
Stages of tumor (TNM)
1&2
(no = 15)
8.1 ± 4.6 9.5 <0.01
3&4
(no = 15)
19.1 ± 15.4
Anova
Ascites
Absent
(No = 14)
10.37 ± 6.72 0.938 >0.05
Mild
(No = 13)
16.96 ± 16.74
Moderate
(No = 3)
14.12 ± 11.72
TNM: tumor-node metastasis system. p< 0.01: highly signiﬁcant.
p> 0.05: non-signiﬁcant.
Table 3 Comparison between pathological criteria of HCC
regarding mean RQ of PDCD4 gene expression in HCC group.
Studied
variables
PDCD4 gene expression
(fold change) in HCC group
(No = 30) (M± SD)
Student t test P-value
Cirrhosis
Positive
(No = 26)
0.69 ± 0.44 0.931 >0.05
Negative
(No = 4)
0.90 ± 0.18
Number of focal lesions
Single
(No = 12)
0.81 ± 0.33 2.39 <0.05
Multiple
(No = 18)
0.50 ± 0.34
Size of tumor
<3 cm
(No = 9)
0.73 ± 0.29 2.68 <0.05
P3 cm
(No = 21)
0.29 ± 0.45
Vascular invasion
Positive
(No = 19)
0.45 ± 0.44 1.73 >0.05
Negative
(No = 11)
0.78 ± 0.60
Enlarged liver
Mild
(No = 27)
0.59 ± 0.53 0.627 >0.05
Moderate
(No = 3)
0.39 ± 0.44
Enlarged spleen
Mild
(No = 20)
0.60 ± 0.50 0.15 >0.05
Moderate
(No = 10)
0.57 ± 0.54
Stage of tumor (TNM)
1&2
(no = 15)
0.97 ± 0.46 13.6 <0.01
3&4
(no = 15)
0.19 ± 0.18
Anova test
Ascites
Absent
(No = 14)
0.61 ± 0.49 0.072 >0.05
Mild
(No = 13)
0.55 ± 0.56
Moderate
(No = 3)
0.50 ± 0.67
PDCD4 gene: programed cell death 4. P< 0.05: signiﬁcant.
p< 0.01: highly signiﬁcant. p> 0.05: non-signiﬁcant.
Circulating MiRNA-21 and PDCD 4 gene expression in HCC 5miR-21 promoted proliferation and protected against apopto-
sis in various tumors (e.g., breast, lung, colon, and liver can-
cers) [16,17].
Consistent with the above studies, this work demonstrated
that miRNA-21 is upregulated in HCC where mean circulating
miRNA-21 RQs in patients with HCC was signiﬁcantly higher
(p< 0.05) compared to that of patients with CLD and healthy
individuals groups, which was in agreement with other
researches [18–20].Please cite this article in press as: El Gedawy G et al., Circulating MiRNA-21 and pro
in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.eCirculating miRNAs originate from tumor tissues, and they
are present in a certain form in the blood and are resistant to
RNase activities [21]. However, it remains unclear how circu-
lating miRNAs originate from tumor tissues. It was suggested
that miRNAs could be derived from dying or lysed tumor cells,
invasive lymphoma cells, cells from tissues affected by long-
term disease, or the active secretion of tumor cells [19].gramed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC)
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Table 4 Comparison of RQ of circulating miRNA-21
between patients with early developed HCC and each of
control and CLD groups.
Early tumor characteristics Mean
± SD
T test P-value
Single nodule (n= 12) 6.15 ± 3.24 T1 = 5.36 P1 < 0.01
T2 = 3.7 P2 < 0.001
Size <3 cm (n= 9) 5.6 ± 2.5 T1 = 5.36 P1 < 0.001
T2 = 3.26 P2 < 0.01
No vascular invasion (n= 11) 7.03 ± 4.4 T1 = 4.44 P1 < 0.01
T2 = 3.24 P2 < 0.01
Stage 1 and 2 (n= 15) 8.1 ± 4.6 T1 = 5.84 P1 < 0.001
T2 = 4.36 P2 < 0.001
T1 and P1: HCC vs. 20 control subjects whose mean miRNA-21
RQ level is 1.13 ± 0.23.
T2 and P2: HCC vs. 20 CLD patients whose mean miRNA-21 RQ
level is 2.38 ± 2.44.
P-value < 0.01: highly signiﬁcant.
Table 5 Pearson’s Correlation between the RQs of each
miRNA-21 and PDCD4 gene and some studied parameters in
HCC group.
Parameters HCC Group
MiRNA21 PDCD4
R p-value r p-value
AST (IU/L) 0.141 >0.05 0.094 >0.05
ALT(IU/L) 0.129 >0.05 0.065 >0.05
TP (g/dl) 0.094 >0.05 0.052 >0.05
Alb (g/dl) 0.271 >0.05 0.201 >0.05
ALP (IU/L) 0.072 >0.05 0.016 >0.05
GGT (IU/L) 0.170 >0.05 0.257 >0.05
T.B (mg/dl) 0.249 >0.05 0.374 <0.05
D.B (mg/dl) 0.314 >0.05 0.437 <0.05
INR 0.218 >0.05 0.102 >0.05
AFP (ng/ml) 0.028 <0.01** 0.078 >0.05
PDCD4 gene: programed cell death 4. P< 0.05: signiﬁcant.
p> 0.05: non-signiﬁcant.
** P< 0.01: highly signiﬁcant.
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Figure 5 ROC curve analysis of AFP.
Figure 6 ROC curve analysis of miRNA-21.
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in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.eOn the contrary, other reports demonstrated that plasma
miRNA-21 levels were higher in patients with hepatitis B than
in those with HCC [22]. An additional study revealed that cir-
culating miRNA-21 levels were lower in patients with hepatitis
B than healthy individuals [23]. The differences in these studies
might be due to different sample sizes or sample selection, dif-
ferences in the RNA extraction procedures or internal controls
used or different ethnic groups and stage of HCC.
In the current study, a signiﬁcant increase (p< 0.01) in the
mean RQ of miRNA-21 was observed with cirrhosis and pro-
gression of HCC, as it showed a signiﬁcant increase in multiple
focal lesions, larger size of tumor, advanced tumor stage and
presence of vascular invasion which indicate that circulating
miRNA-21 could be a potential prognostic marker in HCC.
Meanwhile, no signiﬁcant change of the mean serum AFP
levels was observed regarding the aforementioned parameters
on comparing early and late HCC cases.
These results are consistent with the study done by Wang
et al. [19] who revealed that circulating miRNA-21 levels were
signiﬁcantly higher in advanced HCC compared with early
HCC groups, but serum AFP level was not changed until
tumor appearance.
Also, Faltejskova et al., Hu et al., and Huang et al. [24–26]
showed that overexpression of miRNA-21 was associated with
advanced clinical stage and lymph node metastasis in breast
cancer, colorectal cancer, laryngeal squamous cell carcinoma
and HCC respectively. Furthermore, they indicated that
patients with high miRNA-21 expression had poor prognosis
and poor survival rates compared to patients with lower
miRNA-21 expression.
Many studies have supported the hypothesis that miRNA-
21 overexpression might promote HCC invasion and metasta-
sis through direct or indirect mechanisms, and thus lead to
poor prognosis [17,22,27].
Zhou et al. [28] demonstrated that miRNA-21 promoted
side population cell migration and invasion by targeting PTEN
(Phosphatase and tensin homolog), RECK (Reversion-
inducing cysteine-rich protein with Kazal motifs), and
PDCD4, and that it could also directly target MAP2K3
(mitogen-activated protein-2 kinase-3) and inhibit its expres-
sion during HCC carcinogenesis [29]. Therefore, patients withgramed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC)
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Table 6 Sensitivity, speciﬁcity, PPV, NPV and accuracy of AFP and/or miRNA-21 in HCC group (No = 30) versus non HCC (CLD
and Control) groups (No = 40).
Studied markers Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
Serum AFP at a cut-oﬀ point of 91.7 (ng/mL) 75.2 92.3 90.2 69.2 77.0
Circulating miRNA-21 at cut-oﬀ point of 3.93 RQ 93 90 94.4 87.5 92.5
AFP and/or miRNA-21 88 97 96 90 92
PPV: positive predictive value.
NPV: negative predictive value.
Circulating MiRNA-21 and PDCD 4 gene expression in HCC 7high plasma miRNA-21 expression were shown to have a sig-
niﬁcantly shorter time-to-recurrence compared to those with
low plasma expression [27]. Thus, identiﬁcation of miRNA is
associated with the prognosis of HCC patients, and may not
only elucidate the underlying biological mechanisms involved
in the development or progression of the disease, but also pro-
vide an opportunity to identify novel targets for HCC therapy
[26].
The current study showed that there was a signiﬁcant
increase (p< 0.01) in the mean RQ of circulating miRNA-
21 in patients with early development of HCC (single focal
lesion, no vascular invasion, tumor size less than 3 cm or
TNM stages 1 and 2) compared to each of CLD and control
groups. Thus, plasma mean RQ of miRNA-21 could be used
in the follow up of chronic liver disease patients for early
detection of HCC development.
These ﬁndings were consistent with the results informed by
Wang et al. [19] who stated that changes in plasma miRNA-21
are early and accurately reﬂect the process of the formation of
tumors. Also, Tomimaru and Eguchi [27] reported that circu-
lating miRNA-21 was an independent signiﬁcant factor for
recurrence and was reported to be more sensitive than AFP
for the detection of HCC.
It is reported that, miRNA-21 functions as an anti-
apoptotic factor and this role is at least partially due to the
repression of a highly interconnected tumor suppressor net-
work that includes multiple components of the TP53 (tumor
protein), transforming growth factor beta (TGF b) and apop-
totic pathways [30,31]. Also, several other tumor suppressors
such as PTEN or PDCD4 are regulated by miRNA-21 in dif-
ferent cancer cell types [32].
Tumor suppressor PDCD4 gene is one of the miRNA-21
target genes [12]. PDCD4 gene was identiﬁed as a suppressor
of transformation, tumorigenesis, tumor growth, progression
and invasion [33]. It has been reported that loss or reduction
of PDCD4 expression was found in some malignant tumors
including renal-, lung- and glia-derived tumors [34,17].
In agreement with above studies, the present study showed
that the expression of PDCD4 gene was downregulated in
HCC patients (p< 0.05). Meanwhile, its level did not signiﬁ-
cantly differ between CLD and control groups.
This ﬁnding is consistent with researches showing reduced
PDCD4 expression in lung cancer [35], HCC [36], breast can-
cer [37], glioma [38], pancreatic cancer [13] and esophageal
cancer [39].
The current study also revealed a highly signiﬁcant inverse
correlation (p< 0.01) between mean RQs of miRNA-21 and
PDCD4 mRNA in HCC patients, which could make it a
potential regulator of PDCD4 as its over-expression could
have led to decreased PDCD4-mRNA expression.Please cite this article in press as: El Gedawy G et al., Circulating MiRNA-21 and pro
in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.eZhu et al. and Jiao et al. [17,40] reported the same ﬁndings
in tissue samples from HCC, colorectal cancer and malignant
melanoma. PDCD4 has been shown to be regulated post-
transcriptionally by miRNA-21 in breast [41], colon [12] and
esophageal carcinoma [39].
miRNAs regulate mRNA expression by binding imper-
fectly to their target mRNA; interfering with translation initi-
ation factor binding and relocating the mRNA to cytoplasmic
processing bodies (P-bodies) [42]. Once the mRNA is in the P-
body, it is not translated and may re-enter the cytoplasm, but
can also be degraded over time with a long term expression of
miRNAs [43], which would explain why miRNA-21 is inver-
sely correlated with PDCD4 mRNA.
Also, this study revealed a signiﬁcant decrease of
PDCD4 expression in HCC patients with advanced tumor
stages, increased number of focal lesions and increased
tumor size.
PDCD4 protein expression was signiﬁcantly downregulated
in metastatic HCC tumor tissues and tumor tissues from stages
III to IV patients, and was gradually reduced in HCC cell lines
along with increasing invasive capacity. Inhibition of PDCD4
expression could promote migration and invasion of hepato-
cellular carcinoma cell line (HepG2) cells. Taken together,
these data suggest that PDCD4 is a critical mediator through
which miRNA-21 exerts its biological functions in HCC
[17,44]. These results were in disagreement with those of Chen
et al. [35] who showed that PDCD4 under expression in lung
adenocarcinoma was not associated with tumor size, stage or
nodal status indicating a potential tissue speciﬁc role of
PDCD4 gene.
The fact that PDCD4 is down-regulated in a number of dif-
ferent cancers, including HCC, suggests that restoring its
expression could be a promising mode of therapy [45]. More-
over, delivered PDCD4 facilitated apoptosis, inhibited path-
ways involved in cell proliferation and suppressed pathways
that are known to be involved in tumor angiogenesis, also, reg-
ulated proteins involved in cell-cycle control and suppressed
activator protein-1 (AP-1) activity [46]. Such studies show that
it is possible to effectively deliver a functional PDCD4 gene to
tumors which might help to treat un-resectable HCC tumors in
order to decrease or prevent metastatic spread.
In the current study, the cut-off values and validity of
serum AFP and circulating miRNA-21 for differentiation of
HCC patients from those without HCC (CLD and healthy
subjects) were determined by ROC curves.
ROC curve analysis indicated that, the best cut-off for
serum AFP to differentiate between HCC cases and subjects
without HCC was 91.7 ng/ml. At this cut-off, the sensitivity,
speciﬁcity, PPV, NPP and overall accuracy were 75.2%,
92.3%, 90.2%, 69.2%, and 77.0%, respectively.gramed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC)
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that the best cut-off to differentiate between HCC cases and
non HCC subjects was 3.93 RQ (fold change). At this cut-
off, the sensitivity, speciﬁcity, PPV, NPP and overall accuracy
were 93%, 90%, 94.4%, 87.5%, and 92.5%, respectively with
area under the curve (AUC) of 0.97. This was consistent with
Tomimaru and Eguchi [27] who demonstrated that ROC curve
analysis of circulating miRNA-21 revealed the sensitivity and
speciﬁcity to be 87.3 and 92%, respectively, differentiating
HCC patients from healthy adults and reported that,
miRNA-21 could be a promising biomarker of HCC. This
was in agreement with other studies [18–20].
Furthermore, combined use of serum AFP and circulating
miRNA-21 for detection of HCC cases, had an advantage over
the use ofAFPalone as the sensitivity, speciﬁcity, PPV,NPPand
overall accuracy were increased to 88%, 97%, 96%, 90%, and
92%, respectively. Tomimaru and Eguchi [27] suggested that
the combination of circulating miRNA-21 and serum AFP
enhanced the performance of AFP in discriminating HCC from
healthy volunteers and patients with chronic hepatitis.
As a potential diagnostic biomarker for HCC, Liao et al.
[20] suggested that circulating miRNA-21 possesses several
unique advantages. First, circulating miRNA is non-invasive.
Second, circulating miRNA expression levels are stable and
reproducible [47]. Third, circulating miRNA-21 level cannot
be inﬂuenced by both cirrhosis and viral status. Fourth, signif-
icant overexpression of circulating miRNA-21 was observed
even in patients with early-stage HCC (which is the case in
our study) [27]. Meanwhile, AFP level of 400 ng/ml is consid-
ered as an indicator of HCC in general, and such high level
might not be reached at an early HCC stage. As a result, about
one-third of all HCC cases with small lesions (<3 cm) are not
diagnosed in the early tumor stage. Therefore, circulating
miRNA-21 may serve as a novel co-biomarker to AFP to
improve the diagnostic accuracy of early-stage HCC [48].
The results of this study augmented the aforementioned data
as the circulating miRNA-21 RQ exhibited signiﬁcant elevation
in the early development of HCC (solitary focal lesion, absence
of vascular invasion, tumor size <3 cm, and TNM stages 1 and
2) compared to controls and CLD patients. Also, the sensitivity
and NPV of miRNA-21 were 92% and 87.5% respectively and
for AFP, they were 75.2% and 69.2%, respectively.
Also, the above results give an indication about the proba-
bility of using miRNA-21 as a potential therapeutic target and
this was previously identiﬁed by Khare et al. [49] who pro-
posed that miRNA-21 as a therapeutic target would be effec-
tive since single miRNA can control multiple deranged genes
in HCC.
Moreover, miRNAs have also been shown to inﬂuence sen-
sitivity of tumors to anticancer drugs. HCC cells transfected
with pre-miRNA-21 were resistant to the cytotoxicity induced
by IFN a/5-FU. Therefore, antagomirs targeting miR-21
might be useful in increasing drug efﬁcacy [50].
However, the overexpression of circulating miRNA-21 is
not limited to HCC as its expression was informed in other
human tumors, such as gastric and lung cancers. This indicates
that the increased expression of miRNA-21 is associated to can-
cer development regardless of its kind or origin and may not be
speciﬁc to HCC. Therefore, miRNA-21 alone may not be a
speciﬁc indicator for the diagnosis of HCC in routine clinical
practice, but this marker will progress test performance when
it is used in combination with other biomarkers as AFP [22].Please cite this article in press as: El Gedawy G et al., Circulating MiRNA-21 and pro
in Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.e5. Conclusion
The current study suggests that circulating miRNA-21 could be
novel early diagnostic and prognostic biomarkers for the detec-
tion of HCC. Also, PDCD4 could be an important mediator
through which miRNA-21 exerts its biological functions in
HCC. Thus, approaches interfering with the miRNA-21/
PDCD4-axis, or releasing PDCD4 expression, may have a
strong basis for therapeutic uses in cancer in future. Large scale
and multi-center studies are required to conﬁrm these ﬁndings.
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